We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK drugmaker’s shingles vaccine boosts sales while demand for Covid-related products falls
US drugmaker expects revenues of between $67bn and $71bn this year, down from a record
Amgen to launch ‘biosimilar’ version of medicine that has generated $200bn in sales since launch
DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators
UK biotech racing to keep antibody up to date with latest variants
Short-termism and suspicion in parts of government risk our valuable future in precision medicine
Tight budgets and US reforms are ending a truce between the industry and health authorities
Ubben believes more could be done to isolate the liability to Roundup
Officials row with Pfizer over price as villages struggle to obtain antiviral medication
Beijing’s push to boost the sector has been undermined by reimbursement rules
UK and EU must balance health cost control with plans to grow life sciences
AbbVie and Eli Lilly take action after clawback payments on branded drugs reach a quarter of UK sales
German group’s drugs chief warns EU and UK are dissuading investment as company prioritises US and China
Executives have funding and strategic need for M&A but few are confident to press ahead
Effort to improve health supply chain issues that have led to Greece imposing an export ban on drugs
For all its landmark status, lecanemab may end up representing a triumph of hope over evidence
Covid vaccine maker looks to use machine learning to help discover new treatments
Demand for antiviral treatment has rocketed after jump in infections following Beijing policy U-turn
Inclusive Capital takes €400mn stake as German group grapples with legacy of Monsanto takeover
Sector shows signs of being under-appreciated after an anaemic year
Pharmaceutical groups to part ways with longstanding executives
Agreement is one of several announced as major healthcare conference begins in San Francisco
South Korean vaccine maker looks elsewhere to expand overseas business
High price of treatment and restrictions on medicine developed by Eisai and Biogen will limit patient access initially
Jab developed by CanSinoBio could help nation grappling with a wave of infection
International Edition
